and Germany-based partner BioNTech SE
said Thursday that their booster dose of the omicron BA.4/BA.5-adapted bivalent COVID vaccine for 5-to-11 year olds was recommended for marketing authorization in the the European Union. The EU will review the recommendation from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), and is expected to make a decision “soon.” The companies’ bivalent booster is already authorized in the EU for people at least 12 years old. Pfizer’s stock rose 1.8% in morning trading while BioNTech’s U.S.-listed shares fell 3.3%, while the S&P 500
shot up 4.3%.
Read the original article